Thus, the indirect pharmacological inhibition of MUC4 via canertinib or afatinib could result in developing pan-EGFR inhibitors as a molecular therapeutic agent against advanced pancreatic cancer. This evidence concerns the gene EGFR and familial pancreatic carcinoma.